DEFM14A: Kimberly-Clark to Acquire Kenvue in $36.8B Cash and Stock Deal

Kimberly-Clark Corporation and Kenvue Inc. announce a definitive merger agreement for K-C to acquire Kenvue in a cash and stock transaction valued at approximately $36.8 billion.

Summary

• Kimberly-Clark Corporation (K-C) has entered into a merger agreement to acquire Kenvue Inc. in a two-step merger, with Kenvue becoming a wholly-owned subsidiary of K-C.
• Kenvue stockholders will receive 0.14625 shares of K-C common stock plus $3.50 in cash for each share of Kenvue common stock.
• Based on K-C's closing price on October 31, 2025, the implied value of the per-share merger consideration was approximately $21.01. On December 15, 2025, this value was approximately $18.53.
• Upon completion, K-C stockholders are expected to own approximately 54%, and Kenvue stockholders approximately 46%, of the combined company on a fully diluted basis.
• The transaction is expected to close in the second half of 2026, subject to stockholder and regulatory approvals.
• Both K-C and Kenvue boards of directors have unanimously approved the merger agreement and recommend their respective stockholders vote in favor of the proposals.
• The combined company is projected to generate approximately $32 billion in annual net revenues and approximately $7 billion in adjusted EBITDA for 2025.
• Run-rate synergies of $2.1 billion in total, net of reinvestment, are expected to be achieved within the first three years following closing.

Sentiment

Score: 8

Explanation: The filing presents a strong, unanimous recommendation for a strategic merger with significant anticipated synergies and a clear path to completion, despite acknowledging inherent risks and market volatility. The boards' confidence and the projected financial benefits contribute to a positive sentiment.

Positives

• The merger brings together two complementary portfolios of iconic brands, expected to generate long-term value for stockholders.
• The combined company is anticipated to have enhanced strengths in innovation, selling, and go-to-market capabilities, leading to improved sales growth and profitability.
• Kenvue's science-backed innovations and healthcare professional relationships are expected to accelerate growth when combined with K-C's commercial expertise.
• The acquisition aligns with K-C's 'Powering Care strategy' to focus on higher-growth, higher-margin personal care categories.
• The combined company is expected to have a robust balance sheet and financial foundation, allowing for capital deployment flexibility while maintaining a strong credit profile.
• Exceptional geographic complementarity across a wide range of products is expected to drive global growth through leveraging distribution networks and customer relations.
• The merger consideration represented a premium of approximately 46% over Kenvue's closing price on October 31, 2025, and 15% over its 90-day volume-weighted average price.
• The stock portion of the merger consideration provides Kenvue stockholders with an ownership stake (approximately 46%) in the combined company, allowing participation in future value creation and synergies.
• The mergers are intended to qualify as a tax-free reorganization for U.S. federal income tax purposes, potentially deferring capital gains for Kenvue stockholders on the stock portion.

Negatives

• The market value of the stock consideration will fluctuate with K-C's stock price, creating uncertainty for Kenvue stockholders.
• Existing K-C and Kenvue stockholders will have reduced ownership and less influence over the management of the combined company.
• The merger agreement contains provisions that may discourage alternative transaction proposals, including termination fees.
• Failure to complete the mergers or delays could negatively impact both companies' businesses, financial conditions, and stock prices.
• The integration process may result in unexpected liabilities, costs, loss of key employees, disruption of ongoing businesses, and inconsistencies in standards.
• Business relationships with customers, distributors, and suppliers may be disrupted due to uncertainty associated with the mergers.
• The combined company's indebtedness will be substantially greater than K-C's standalone debt, potentially reducing business flexibility and increasing vulnerability to adverse economic conditions.
• Declaration, payment, and amounts of future dividends for K-C stockholders are uncertain and at the discretion of the K-C board.
• The combined company may record goodwill and other intangible assets that could become impaired, leading to material non-cash charges.
• Shares of K-C common stock received by Kenvue stockholders will have different rights than Kenvue common stock.
• The market price of K-C common stock may decline due to sales by former Kenvue stockholders or current K-C stockholders post-merger.

Risks

• The number of shares of K-C common stock issuable in the first merger is fixed and will not be adjusted, meaning Kenvue stockholders cannot be sure of the market value of the stock consideration due to K-C stock price fluctuations.
• K-C stockholders and Kenvue stockholders will have reduced ownership in the combined company and less influence over management.
• The mergers may not be completed, and the merger agreement may be terminated, leading to negative impacts on businesses, results of operations, financial conditions, and stock prices.
• The merger agreement limits the ability of either K-C or Kenvue to pursue alternatives and may require a termination fee payment under specified circumstances.
• Failure to complete the mergers, or a delay in closing, could negatively impact K-C's or Kenvue's respective businesses, results of operations, financial conditions, and stock prices.
• Directors and executive officers of each company have interests in the mergers that may differ from those of other stockholders.
• Unaudited pro forma condensed combined financial information is based on preliminary estimates and assumptions, and actual future results may differ materially.
• Opinions of financial advisors will not reflect changes in circumstances between the signing of the merger agreement and the closing of the mergers.
• Forecasted financial information is based on various estimates and assumptions that may not be realized, potentially affecting K-C's stock price post-merger.
• Uncertainties associated with the mergers may cause a loss of management personnel and other key employees.
• Business relationships of K-C and Kenvue may be disrupted due to uncertainty associated with the mergers.
• Consummation of the mergers may trigger change-in-control or other provisions in certain agreements.
• The need for regulatory approvals may delay the closing date or diminish the benefits of the mergers.
• K-C or Kenvue may waive one or more closing conditions without re-soliciting stockholder approval.
• The merger agreement subjects K-C and Kenvue to restrictions on their respective business activities prior to the effective times of the mergers.
• K-C and Kenvue will incur significant costs in connection with the mergers, potentially in excess of those anticipated.
• Litigation relating to the mergers could result in an injunction preventing closing and/or substantial costs.
• The indebtedness of the combined company will be substantially greater than K-C's standalone indebtedness, affecting business flexibility.
• Declaration, payment, and amounts of dividends, if any, distributed to K-C stockholders will be uncertain.
• The combined company may record goodwill and other intangible assets that could become impaired, resulting in material non-cash charges.
• Shares of K-C common stock received by Kenvue stockholders will have different rights from shares of Kenvue common stock.
• The market price of K-C common stock may decline in the future as a result of the sale of shares by former Kenvue stockholders or current K-C stockholders.
• The exclusive-forum provision in K-C's by-laws could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• If the mergers fail to qualify as a reorganization for U.S. federal income tax purposes, Kenvue stockholders may be required to pay additional U.S. federal income taxes.
• Existing and potential litigation, regulatory, and reputational risks related to Kenvue's product portfolio (e.g., acetaminophen, talc) could affect the combined company.

Future Outlook

The combined company is expected to become a leading global health and wellness entity, leveraging complementary brands, categories, and geographic strengths to drive profitable growth. Management anticipates achieving $2.1 billion in run-rate synergies, net of reinvestment, within three years post-closing, leading to an enhanced financial profile with improved growth and profitability. The company is committed to maintaining a robust credit profile to support strategic capital investment for long-term growth.

Management Comments

• Michael D. Hsu, Chairman of the Board and Chief Executive Officer of Kimberly-Clark Corporation, and Kirk L. Perry, Chief Executive Officer and Director of Kenvue Inc., jointly expressed their support for the merger.
• The K-C board unanimously determined that the merger agreement and transactions are fair to, and in the best interests of K-C and its stockholders, and unanimously recommends voting FOR the K-C issuance proposal and K-C adjournment proposal.
• The Kenvue board unanimously determined that it is fair to, and in the best interests of, Kenvue and its stockholders, and unanimously recommends voting FOR the Kenvue merger proposal, Kenvue advisory compensation proposal, and Kenvue adjournment proposal.

Industry Context

This acquisition represents a significant consolidation in the consumer health and personal care sectors, creating a diversified global leader. It aligns with Kimberly-Clark's 'Powering Care strategy' to pivot towards higher-growth, higher-margin personal care categories. The merger aims to capitalize on complementary brand portfolios, innovation capabilities, and geographic distribution networks to address evolving consumer needs and drive market leadership.

Comparison to Industry Standards

• J.P. Morgan's public trading multiples analysis for Kenvue used a FV/2026E Adjusted EBITDA (post-SBC) multiple reference range of 11.0x to 15.0x, indicating an implied equity value per share of $14.50 to $21.50, compared to the implied consideration of $21.01.
• J.P. Morgan's public trading multiples analysis for K-C used a FV/2026E Adjusted EBITDA (post-SBC) multiple reference range of 11.0x to 15.0x, indicating an implied equity value per share of $111.50 to $156.00, compared to K-C's closing price of $119.71.
• J.P. Morgan's transaction multiples analysis for Kenvue used a FV/LTM adjusted EBITDA (post-SBC) multiple reference range of 14.0x to 19.0x, indicating an implied per-share equity value of $20.00 to $28.50, compared to the implied consideration of $21.01.
• PJT Partners' selected comparable company analysis for Kenvue used a TEV/2026E adjusted EBITDA (post-SBC) multiple range of 12.0x to 16.0x, yielding implied prices per share of $16.50 to $23.00.
• PJT Partners' selected comparable company analysis for K-C used a TEV/2026E adjusted EBITDA (post-SBC) multiple range of 12.0x to 16.0x, yielding implied prices per share of $122.50 to $167.00.
• Centerview's selected public comparable companies analysis for Kenvue used an enterprise value to estimated 2026 EBITDA multiple reference range of 12.0x to 14.0x, resulting in implied per share equity values of $18.07 to $21.73.
• Centerview's selected public comparable companies analysis for K-C used an enterprise value to estimated 2026 EBITDA multiple reference range of 11.0x to 13.0x, resulting in implied per share equity values of $119.14 to $141.25.
• Goldman Sachs' premia paid analysis for transactions with mixed cash and stock consideration (over $5 billion EV, 40-50% target ownership) indicated a median premium of 19%, with a range of 8% to 28%. The merger consideration implied a 46% premium over Kenvue's closing price on October 31, 2025.

Management Changes

Corporate Governance

Legal Proceedings

• On December 8, 2025, a purported Kenvue stockholder filed a lawsuit (Steinbrecher v. Kenvue Inc. et al.) in the U.S. District Court for the Eastern District of Wisconsin, alleging material omissions or misstatements in the preliminary joint proxy statement/prospectus and seeking to enjoin the mergers.
• Kenvue has received demand letters from purported stockholders alleging disclosure deficiencies in the preliminary joint proxy statement/prospectus.
• Ongoing acetaminophen-related litigation, including a petition filed by Informed Consent Action Network requesting safety-related labeling changes for over-the-counter acetaminophen-containing drug products during pregnancy.
• A lawsuit filed on October 28, 2025, by the Attorney General of Texas against Kenvue, Kenvue Brands LLC, and J&J, alleging violations of consumer protection acts related to prenatal and early-childhood exposure to acetaminophen and autism spectrum disorder/ADHD.
• Claims for personal injury and consequential death related to Johnson's Baby Powder were brought against Kenvue UK Limited in the Business and Property Courts in Manchester on October 16, 2025.

Related Party Transactions

• Contracts between Kenvue or any Kenvue Subsidiary and Johnson & Johnson or any Affiliates of Johnson & Johnson related to the separation of the Kenvue business (Separation Agreement) are considered material contracts.

Stakeholder Impact

• Shareholders of Kenvue will receive a mix of cash and K-C common stock, allowing them to participate in the future value of the combined company.
• Shareholders of K-C will experience dilution of ownership in the combined company (expected to own ~54% post-merger).
• Employees of both companies may experience uncertainty regarding their roles and potential disruptions during the integration process.
• Key management personnel and other employees are subject to retention and severance benefits, aiming to ensure continuity.
• Customers, distributors, suppliers, and other business partners may face disruptions or renegotiations of existing relationships.
• Creditors of Kenvue will see their existing indebtedness reviewed, with potential refinancing, repurchase, or exchange by K-C, impacting their investment.

Next Steps

• K-C stockholders will vote on the issuance of K-C common stock in connection with the first merger at a special meeting on January 29, 2026.
• Kenvue stockholders will vote on adopting the merger agreement and related transactions at a special meeting on January 29, 2026.
• Both companies will seek necessary regulatory approvals, including under the HSR Act, other Antitrust Laws, and Foreign Investment Laws.
• K-C will work to list the newly issued K-C common stock on Nasdaq.
• Kenvue common stock will be delisted from the NYSE and deregistered under the Exchange Act as soon as practicable after the first effective time.
• The merger is expected to close in the second half of 2026.

Key Dates

Recommendation

The acquisition of Kenvue by Kimberly-Clark is a highly strategic move that promises significant value creation through enhanced market position, complementary brand portfolios, and substantial cost and growth synergies totaling $2.1 billion. The combined entity is projected to achieve $32 billion in annual net revenues and $7 billion in adjusted EBITDA, indicating a robust financial outlook. While integration risks and increased indebtedness are present, the unanimous board support and the premium offered to Kenvue shareholders suggest a well-considered transaction with strong long-term potential. The fixed exchange ratio allows Kenvue shareholders to benefit from any future appreciation in K-C's stock, making it an attractive proposition for investors seeking exposure to a diversified global consumer health and personal care leader.

Keywords

Kimberly-Clark, Kenvue, Merger, Acquisition, Consumer Health, Personal Care, Household Products, SEC Filing, Proxy Statement, Stockholder Vote, Synergies, M&A, KMB, KVUE